Design and synthesis of a library of chemokine antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6249-6252

  Bhalay, Gurdip ^a   Albrecht, Birgit ^a   Akhlaq, Mohammed ^a   Baettig, Urs ^a   Beer, David ^a   Brown, Zarin ^a   Charlton, Steven ^a   Dunstan, Andrew ^a   Bradley, Michelle ^a   Gedeck, Peter ^a   Glen, Angela ^a   Howea, Trevor ^a   Keller, Thomas ^a   Leighton Davies, Juliet ^a   Li, Alice ^a   McCarthy, Clive ^a   Mocquet, Cecile ^a   Owen, Charles ^a   Nicklin, Paul ^a   Rosethorne, Elizabeth ^a  

^a Novartis Institutes of Biomedical Research   (United Kingdom)

Author keywords

Antagonist; Chemokine; Library; Solid phase

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MONOMER; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; LIBRARY; PHARMACOPHORE; SOLID PHASE SYNTHESIS; STRUCTURE ANALYSIS;

EID: 80054777639     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.013     Document Type: Article

References (18)

1. Monika, S. Crit. Rev. Biotechnol. 2010, 30, 1.
2. Saunders, J.; Tarby, C. M. Drug Discov. Today 1999, 4, 80.
3. Horuk, R.; Ng, H. P. Med. Res. Rev. 2000, 20, 155.
4. Perry, C. M. Drugs 2010, 70, 1189.
5. Steinberg, M.; Silva, M. Clin. Therapeut. 2010, 32, 821.
6. For leading ref to patent structures see: Proudfoot, A. E. I.; Power, C. A.; Schwarz, M. K. Exp. Opin. Invest. Drugs 2010, 19, 345.
7. Liang, M.; Mallari, C.; Rosser, M.; Ng, H.; May, K.; Monahan, S.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Shaw, K.; Wei, G.-P.; Xu, W.; Zhao, Z.; Ho, E.; Shen, J.; Oanh, H.; Subramanyam, B.; Vergona, R.; Taub, D.; Dunning, L.; Harvey, S.; Snider, R. M.; Hesselgesser, J.; Morrissey, M. M.; Perez, H. D.; Horuk, R. J. Biol. Chem. 2000, 275, 19000.
8. Forbes, I. T.; Cooper, D. G.; Dodds, E. K.; Hickey, D. M. B.; Ife, R. J.; Meeson, M.; Stockley, M.; Berkhout, T. A.; Gohil, J.; Groot, P. H. E.; Moores, K. Bioorg. Med. Chem. Lett. 2000, 10, 1803.
9. Gong, L.; Kertesz, D. J.; Smith, D. B.; Wilhelm, R. S. World Patent Application WO 2000029377.
10. Baroudy, B. M.; Clader, J. W.; Josien, H. B.; McCombie, S. W.; McKittrick, B. A.; Miller, M. W.; Neustadt, B. R.; Palani, A.; Steensma, R.; Tagat, J. R.; Vice, S. F.; Laughlin, M. A. World Patent Application WO 2000066559.
11. Pease, J. E.; Horuk, R. Curr. Top. Med. Chem. 2010, 10, 1351.
12. Pasternak, A.; Goble, D. S.; Struthers, M.; Pasquale, P. V.; Ayala, J. M.; Di Salvo, J.; Kilburn, R.; Wisniewski, T.; DeMartino, J. A.; Mills, S. G.; Yang, L. A. C. S. Med. Chem. Lett. 2010, 1, 14.
13. Bhattacharyya, S. Curr. Opin. Drug Disc. Dev. 2004, 6, 752-764.
14. Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. J. Med. Chem. 2001, 44, 1313.
15. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Del. Rev. 2001, 46, 3.
16. Reagents for solid-phase chemistry were purchased from: Agilent Technologies or Merck Biosciences.
17. A representative set of 1H NMR were also aquired on the library collection (220 sampled, approx 8% of the collection).
18. Antagonist activity was confirmed for selected compounds using functional assays.